Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
Abstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, h...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/39b74ac02205476a9300ff36cbb33d6d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:39b74ac02205476a9300ff36cbb33d6d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:39b74ac02205476a9300ff36cbb33d6d2021-12-02T16:24:23ZEvaluation of multiple transcriptomic gene risk signatures in male breast cancer10.1038/s41523-021-00301-02374-4677https://doaj.org/article/39b74ac02205476a9300ff36cbb33d6d2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00301-0https://doaj.org/toc/2374-4677Abstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.Jane BayaniCoralie PoncetCheryl CrozierAnouk NevenTammy PiperCarrie CunninghamMonika SobolStefan AebiKim BensteadOliver BoglerLissandra Dal LagoJudith FraserFlorentine HilbersIngrid HedenfalkLarissa KordeBarbro LinderholmJohn MartensLavinia MiddletonMelissa MurrayCatherine KellyCecilia NilssonMonika NowaczykStephanie PeetersAleksandra PericPeggy PorterCarolien SchröderIsabel T. RubioKathryn J. RuddyChristi van AsperenDanielle Van Den WeyngaertCarolien van DeurzenElise van Leeuwen-StokJoanna VermeijEric WinerSharon H. GiordanoFatima CardosoJohn M. S. BartlettNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jane Bayani Coralie Poncet Cheryl Crozier Anouk Neven Tammy Piper Carrie Cunningham Monika Sobol Stefan Aebi Kim Benstead Oliver Bogler Lissandra Dal Lago Judith Fraser Florentine Hilbers Ingrid Hedenfalk Larissa Korde Barbro Linderholm John Martens Lavinia Middleton Melissa Murray Catherine Kelly Cecilia Nilsson Monika Nowaczyk Stephanie Peeters Aleksandra Peric Peggy Porter Carolien Schröder Isabel T. Rubio Kathryn J. Ruddy Christi van Asperen Danielle Van Den Weyngaert Carolien van Deurzen Elise van Leeuwen-Stok Joanna Vermeij Eric Winer Sharon H. Giordano Fatima Cardoso John M. S. Bartlett Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
| description |
Abstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa. |
| format |
article |
| author |
Jane Bayani Coralie Poncet Cheryl Crozier Anouk Neven Tammy Piper Carrie Cunningham Monika Sobol Stefan Aebi Kim Benstead Oliver Bogler Lissandra Dal Lago Judith Fraser Florentine Hilbers Ingrid Hedenfalk Larissa Korde Barbro Linderholm John Martens Lavinia Middleton Melissa Murray Catherine Kelly Cecilia Nilsson Monika Nowaczyk Stephanie Peeters Aleksandra Peric Peggy Porter Carolien Schröder Isabel T. Rubio Kathryn J. Ruddy Christi van Asperen Danielle Van Den Weyngaert Carolien van Deurzen Elise van Leeuwen-Stok Joanna Vermeij Eric Winer Sharon H. Giordano Fatima Cardoso John M. S. Bartlett |
| author_facet |
Jane Bayani Coralie Poncet Cheryl Crozier Anouk Neven Tammy Piper Carrie Cunningham Monika Sobol Stefan Aebi Kim Benstead Oliver Bogler Lissandra Dal Lago Judith Fraser Florentine Hilbers Ingrid Hedenfalk Larissa Korde Barbro Linderholm John Martens Lavinia Middleton Melissa Murray Catherine Kelly Cecilia Nilsson Monika Nowaczyk Stephanie Peeters Aleksandra Peric Peggy Porter Carolien Schröder Isabel T. Rubio Kathryn J. Ruddy Christi van Asperen Danielle Van Den Weyngaert Carolien van Deurzen Elise van Leeuwen-Stok Joanna Vermeij Eric Winer Sharon H. Giordano Fatima Cardoso John M. S. Bartlett |
| author_sort |
Jane Bayani |
| title |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
| title_short |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
| title_full |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
| title_fullStr |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
| title_full_unstemmed |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
| title_sort |
evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/39b74ac02205476a9300ff36cbb33d6d |
| work_keys_str_mv |
AT janebayani evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT coralieponcet evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT cherylcrozier evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT anoukneven evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT tammypiper evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT carriecunningham evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT monikasobol evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT stefanaebi evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT kimbenstead evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT oliverbogler evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT lissandradallago evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT judithfraser evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT florentinehilbers evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT ingridhedenfalk evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT larissakorde evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT barbrolinderholm evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT johnmartens evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT laviniamiddleton evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT melissamurray evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT catherinekelly evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT cecilianilsson evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT monikanowaczyk evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT stephaniepeeters evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT aleksandraperic evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT peggyporter evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT carolienschroder evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT isabeltrubio evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT kathrynjruddy evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT christivanasperen evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT daniellevandenweyngaert evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT carolienvandeurzen evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT elisevanleeuwenstok evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT joannavermeij evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT ericwiner evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT sharonhgiordano evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT fatimacardoso evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT johnmsbartlett evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer |
| _version_ |
1718384103983677440 |